➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Medtronic
AstraZeneca
McKinsey
Mallinckrodt

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

Sodium iodide i-123 - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for sodium iodide i-123 and what is the scope of freedom to operate?

Sodium iodide i-123 is the generic ingredient in one branded drug marketed by Cardinal Health 418, Curium, and Ge Healthcare, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There are one thousand four hundred and seventy-two drug master file entries for sodium iodide i-123. Two suppliers are listed for this compound.

Recent Clinical Trials for sodium iodide i-123

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AHS Cancer Control AlbertaPhase 1
Alberta Cancer FoundationPhase 1
Oxford University Hospitals NHS TrustPhase 1/Phase 2

See all sodium iodide i-123 clinical trials

US Patents and Regulatory Information for sodium iodide i-123

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Curium SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 071910-001 Feb 28, 1989 AA RX No No   Start Trial   Start Trial   Start Trial
Ge Healthcare SODIUM IODIDE I 123 sodium iodide i-123 SOLUTION;ORAL 017630-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Cardinal Health 418 SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 018671-002 May 27, 1982 AA RX Yes Yes   Start Trial   Start Trial   Start Trial
Cardinal Health 418 SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 018671-003 May 27, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Merck
Baxter
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.